Eli Lilly Bets $2.25B on Profluent's AI Gene-Editing Tech
Eli Lilly (LLY) has announced a $2.25 billion research and development agreement with Profluent to harness AI for discovering and developing recombinases for precise, large-scale gene editing.
Key Numbers
Eli Lilly (NYSE: LLY) has entered into a research and development agreement with biotechnology company Profluent valued at up to $2.25 billion, as reported by Pharmaceutical Technology. The partnership aims to leverage artificial intelligence to discover and develop recombinases for precise, large-scale gene editing.
Deal Details
| Item | Detail |
|---|---|
| Total Value | $2.25 billion |
| Buyer | Eli Lilly |
| Seller | Profluent |
| Focus | AI-driven gene editing |
| Status | Pending closing |
Specific upfront and milestone payments have not been disclosed.
Rationale
Eli Lilly seeks to bolster its gene editing capabilities, particularly for precise genetic therapies targeting difficult diseases. Recombinase technology enables large and precise genetic modifications, potentially opening new avenues for treating genetic disorders.
Regulatory Challenges
The deal is expected to undergo regulatory review in the US and EU due to the sensitivity of gene editing technologies. No obstacles have been announced yet.
Impact on Stock
Eli Lilly's stock (LLY) showed no significant change following the announcement, as the market views the deal as a long-term investment. Future success in developing gene therapies could enhance the stock's value.
Frequently Asked Questions
Found this useful? Share it